第四色官方网站 ESMO 2024 | 消化系统肿瘤领域LBA和Oral一文汇总
发布日期：2024-09-06 12:31 点击次数：117
弁言
2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，当作肿瘤内科最高鸿沟的外洋嘉会，波及肺癌、乳腺癌、消化谈肿瘤、泌尿生殖系统肿瘤等领域的多项琢磨届时齐将裸露最新阐述。
现在，ESMO官网照旧公布本次入选大会的LBA、Oral（O）和Mini oral（MO）标题，村上里沙作品及图片本文特将部分消化系统肿瘤干系选录标题进行整理，分为胃癌、肠癌、肝细胞癌、胰腺癌、胃肠谈间质瘤，以飨读者。（注：本文不分先后法律施展）
胃癌
选录号：LBA58
A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG， TROG， EORTC and CCTG
选录号：LBA59
Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial
选录号：LBA60
Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
讲演各人：彭智（北京大学肿瘤病院）
选录号：1400O
Final overall survival for the phase 3， KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced， unresectable or metastatic G/GEJ adenocarcinoma
选录号：609O
CLDN18.2 targeted antibody-drug conjugate (ADC)， SHR-A1904， in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study
选录号：1401O
Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal， gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
选录号：1402MO
An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophage
肠癌
结肠癌
选录号：LBA24
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
色狗选录号：63O
Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial
选录号：503O
Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
选录号：512O
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III， Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial
结直肠癌
选录号：LBA25
Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
选录号：LBA26
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
选录号：502O
Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial
选录号：504O
IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort
选录号：505O
Sotorasib (soto)， panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study
选录号：506O
Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO
选录号：507O
Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial
选录号：511MO
Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial
选录号：513MO
Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1， an open-label， phase 1b/2 study
选录号：514MO
The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
选录号：515MO
Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI)
选录号：516MO
Zanidatamab (Zani) + Chemotherapy (CT) in First-Line (1L) Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC)
选录号：518MO
Update analysis of the randomized phase II study comparing FOLFIRI plus (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
直肠癌
选录号：508MO
Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
选录号：509O
Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial
肝细胞癌
选录号：LBA3
Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study
选录号：LBA38
Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized， open-label， phase 2/3 study (DUBHE-H-308)
选录号：LBA39
Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
选录号：LBA40
Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
选录号：947MO
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
选录号：965MO
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from CheckMate 9DW
胰腺癌
选录号：LBA62
Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44
选录号：LBA63
A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
选录号：608O
Preliminary safety and clinical activity of ASP3082， afirst-in-class， KRAS G12D selective protein degrader in adults with advanced pancreatic (PC)， colorectal (CRC)， and non-small cell lung cancer (NSCLC)
选录号：1504MO
Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD)， (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum
胃肠谈间质瘤
选录号：LBA79
LENVAGIST - A multicentre， comparative， placebo (P)-controlled， double-blinded， phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib
选录号：1722MO
Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
选录号：1723MO
Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST)
外洋会议专区
博医荟陪你拓宽外洋视线
原文贯穿 | https://mp.weixin.qq.com/s/7oDSpBlKkpu_sYz6jaVnwQ
施行源流 | 公众号：医学界肿瘤频谈
排版 | 赵微
审核 | 方玥立、贾冬雪第四色官方网站
phasewith选录andcancer发布于：河南省声明：该文不雅点仅代表作家本东谈主，搜狐号系信息发布平台，搜狐仅提供信息存储空间工作。